DUBLIN, January 4, 2021 / PRNewswire / – Added Report “RNAi Drug Delivery Market (RNAi): Global Industry Trend, Share, Size, Growth, Opportunity and 2020-2025 Estimate” ResearchAndMarkets.com’s offering.
The global RNA (RNAi) drug delivery market grew at a CAGR of about 7% in 2014-2019. Delivery of ribonucleic acid (RNAi) drugs refers to a therapeutic solution to monitor gene expression or mutations. RNAi drug delivery is usually administered through intravenous, intra-dermal and intraperitoneal injection and conventional delivery methods. It includes nanoparticle, pulmonary, nucleic acid and aptamer drug delivery technologies. These technologies are also used to analyze gene functions in eukaryotes and to develop therapeutic gene temperature solutions. As a result, the delivery of RNAi drugs is widely used for the treatment of infectious diseases, chronic metabolic disorders, cardiovascular, neurological, urological, oncological and ophthalmological disorders.
More and more medical and genetic disorders, such as cancers and cardiovascular diseases (CVDs) across the globe, represent one of the key drivers of market growth. In addition, the increase in geriatric numbers, which is more susceptible to such diseases, is also driving the growth of the market. Accordingly, as coronavirus infection (COVID-19) continues to spread worldwide, there has been a significant increase in the demand for RNAi drug delivery technologies. Targeted delivery methods, such as aptamer drug delivery systems, are gaining great traction for antiviral drug administration because they are stimulated by small interrelated RNAs (siRNAs) that may inhibit the delivery of antivirals. express viral antigens.
In addition, a number of technological advances, such as the development of innovative synthetic delivery carriers and biomarkers, are expected to drive market growth. The nanocarriers, including siRNAs or microRNAs (miRNAs), are essential for the development of personalized pharmaceuticals and the identification of cellular molecules and altered metabolites. Other factors, including extensive research and development (R&D) activities in the fields of nanotechnology and molecular diagnostics, along with overall improvements in healthcare infrastructure, are expected to drive the market further. Looking ahead, the publisher expects the global RNA (RNAi) drug delivery market to continue to grow moderately over the next five years.
Competitive Landscape:
The report has also examined the competitive landscape of the market with some of the key players Alnylam Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., CureVac AG, Dicerna Pharmaceuticals Inc., Gradalis Inc., Ionis Pharmaceuticals Inc., Merck & Co. Inc. , Moderna Inc., Quark Pharmaceuticals Inc. (SBI ALApharma Co. Limited), Silence Therapeutics Plc and Sirnaomics Inc.
Key questions answered in this report:
- How has the global RNA (RNAi) drug delivery market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global RNA (RNAi) interventional drug delivery market?
- What are the main regional markets?
- What is application-based market disruption?
- What is technology-based market disruption?
- What are the different levels in the business value chain?
- What are the key drivers and challenges in the industry?
- What is the structure of the global RNA (RNAi) drug delivery market and who are the key players?
- What is the level of competition in the industry?
Key topics covered:
1 Introduction
2 Scope and Approach
2.1 Aims of the study
2.2 Stakeholders
2.3 Data sources
2.3.1 Key Sources
2.3.2 Secondary Sources
2.4 Market measurement
2.4.1 Bottom up approach
2.4.2 A top-down approach
2.5 Preview Procedure
3 Executive Minutes
4 Introduction
4.1 Outlook
4.2 Key industry trends
5 Global RNA Intervention Drug Delivery Market (RNAi)
5.1 Market outlook
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market outlook
6 Market breakdown by bid
6.1 Infectious disease
6.1.1 Market trends
6.1.2 Market outlook
6.2 Cardiology
6.2.1 Market trends
6.2.2 Market forecast
6.3 Oncology
6.3.1 Market trends
6.3.2 Market forecast
6.4 Neurology
6.4.1 Market trends
6.4.2 Market outlook
6.5 Ophthalmology
6.5.1 Market trends
6.5.2 Market forecast
6.6 Urology
6.6.1 Market trends
6.6.2 Market outlook
6.7 Metabolic disorders
6.7.1 Market trends
6.7.2 Market forecast
6.8 Other
6.8.1 Market trends
6.8.2 Market forecast
7 Market breakdown with technology
7.1 Nanoparticle Drug Delivery
7.1.1 Market trends
7.1.2 Market outlook
7.2 Delivery of Pulmonary Drugs
7.2.1 Market trends
7.2.2 Market forecast
7.3 Delivery of Nucleic Acid Drugs
7.3.1 Market trends
7.3.2 Market forecast
7.4 Aptamer Drug Delivery
7.4.1 Market trends
7.4.2 Market forecast
7.5 Other
7.5.1 Market trends
7.5.2 Market outlook
8 Market breakdown by area
8.1 North America
8.1.1 United States
8.1.1.1 Market trends
8.1.1.2 Market outlook
8.1.2 Canada
8.1.2.1 Market trends
8.1.2.2 Market outlook
8.2 Asia Pacific
8.2.1 China
8.2.1.1 Market trends
8.2.1.2 Market outlook
8.2.2 Japan
8.2.2.1 Market trends
8.2.2.2 Market forecast
8.2.3 India
8.2.3.1 Market trends
8.2.3.2 Market forecast
8.2.4 South Korea
8.2.4.1 Market trends
8.2.4.2 Market outlook
8.2.5 Australia
8.2.5.1 Market trends
8.2.5.2 Market forecast
8.2.6 Indonesia
8.2.6.1 Market trends
8.2.6.2 Market outlook
8.2.7 Other
8.2.7.1 Market trends
8.2.7.2 Market forecast
8.3 Europe
8.3.1 Germany
8.3.1.1 Market trends
8.3.1.2 Market outlook
8.3.2 France
8.3.2.1 Market trends
8.3.2.2 Market forecast
8.3.3 United Kingdom
8.3.3.1 Market trends
8.3.3.2 Market forecast
8.3.4 Italy
8.3.4.1 Market trends
8.3.4.2 Market forecast
8.3.5 Spain
8.3.5.1 Market trends
8.3.5.2 Market forecast
8.3.6 Russia
8.3.6.1 Market trends
8.3.6.2 Market outlook
8.3.7 Other
8.3.7.1 Market trends
8.3.7.2 Market forecast
8.4 Latin America
8.4.1 Brazil
8.4.1.1 Market trends
8.4.1.2 Market outlook
8.4.2 Mexico
8.4.2.1 Market trends
8.4.2.2 Market forecast
8.4.3 Other
8.4.3.1 Market trends
8.4.3.2 Market forecast
8.5 Middle East and Africa
8.5.1 Market trends
8.5.2 Market breakdown by country
8.5.3 Market forecast
9 SWOT analysis
9.1 Preview
9.2 Strengths
9.3 Weaknesses
9.4 Opportunity
9.5 Dangers
10 Value chain analysis
11 Five Force Porters Survey
11.1 Preview
11.2 Buyer’s bargaining power
11.3 Bargaining power of suppliers
11.4 Competition Level
11.5 The Risk of New Entrants
11.6 Agent Risk
12 Price Review
13 Competitive Landscape
13.1 Market Structure
13.2 Key players
13.3 Profiles of key players
13.3.1 Alnylam Pharmaceuticals Inc.
13.3.1.1 Company forecast
13.3.1.2 Product Package
13.3.1.3 Finance
13.3.1.4 SWOT Analysis
13.3.2 Arrowhead Pharmaceuticals Inc.
13.3.2.1 Company forecast
13.3.2.2 Product Package
13.3.2.3 Finance
13.3.3 CureVac AG
13.3.3.1 Company forecast
13.3.3.2 Product Package
13.3.3.3 Finance
13.3.4 Dicerna Pharmaceuticals Inc.
13.3.4.1 Company forecast
13.3.4.2 Product Package
13.3.4.3 Finance
13.3.5 Gradalis Inc.
13.3.5.1 Company forecast
13.3.5.2 Product Package
13.3.6 Ionis Pharmaceuticals Inc.
13.3.6.1 Company forecast
13.3.6.2 Product Package
13.3.6.3 Finance
13.3.6.4 SWOT Analysis
13.3.7 Merck & Co. Inc.
13.3.7.1 Company forecast
13.3.7.2 Product Package
13.3.7.3 Finance
13.3.7.4 SWOT Analysis
13.3.8 Moderna Inc.
13.3.8.1 Company Review
13.3.8.2 Product Package
13.3.8.3 Finance
13.3.9 Quark Pharmaceuticals Inc. (SBI ALApharma Co. Limited)
13.3.9.1 Company forecast
13.3.9.2 Product Package
13.3.10 Silence Therapeutics Plc
13.3.10.1 Company forecast
13.3.10.2 Product Package
13.3.10.3 Finance
13.3.11 Sirnaomics Inc.
13.3.11.1 Company forecast
13.3.11.2 Product Package
For more information about this report, visit https://www.researchandmarkets.com/r/nofvz
Research and Markets also offers Custom Search services providing targeted, complete and unique search.
Contact the media:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For EST Office Hours Call + 1-917-300-0470
For US / CAN Toll Free Call + 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
US Fax: 646-607-1904
Fax (outside the US): +353-1-481-1716
SOURCE Research and Markets
Related Links
http://www.researchandmarkets.com